Kamada (KMDA) Return on Invested Capital (2017 - 2026)
Kamada (KMDA) posted quarterly Return on Invested Capital of 5.59% for Q1 2026, up 558.0% year-on-year from 0.85% in Q1 2025, and down 4.42% on a QoQ basis from 5.85% in Q4 2025.
Kamada (KMDA) Return on Invested Capital (2017 - 2026) Analysis & Trends
Kamada (KMDA) has reported Return on Invested Capital for 9 consecutive years, with 5.59% the latest figure, recorded in Q1 2026.
- Quarterly Return on Invested Capital rose 558.0% year-over-year to 5.59% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 5.59% (up 558.0% YoY) and the FY2025 annual result came in at 0.03%, up 2.0% from the prior year.
- Return on Invested Capital slipped to 5.59% in Q1 2026 per KMDA's latest filing, from 5.85% in the prior quarter.
- Over the last five years, Return on Invested Capital for KMDA reached as high as 5.85% in Q4 2025 and fell as low as 0.0% in Q1 2022.
- A 5-year average of 1.48% and a median of 0.33% in 2023 frame the typical range for Return on Invested Capital.
- The largest YoY upside for Return on Invested Capital was 584 bps in 2025 against a maximum downside of 68 bps in 2025.
- Year by year, Return on Invested Capital stood at 0.27% in 2022, then jumped by 66 bps to 0.45% in 2023, then sank by 99 bps to 0.01% in 2024, then jumped by 110465 bps to 5.85% in 2025, then fell by 4 bps to 5.59% in 2026.
- According to Business Quant data, Return on Invested Capital over the past three periods registered 5.59%, 5.85%, and 5.34% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 0.01% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 0.01% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 0.00% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.00% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 0.03% |
| 10 | Kamada | 401.22 Mn | 328.07 Mn | 19.12 Mn | 5.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.59% |
| Dec 31, 2025 | 5.85% |
| Sep 30, 2025 | 5.34% |
| Jun 30, 2025 | 5.02% |
| Mar 31, 2025 | 0.01% |
| Dec 31, 2024 | 0.01% |
| Sep 30, 2024 | 0.00% |
| Jun 30, 2024 | 0.70% |
| Mar 31, 2024 | 0.69% |
| Dec 31, 2023 | 0.45% |
| Sep 30, 2023 | 0.33% |
| Jun 30, 2023 | 0.22% |
| Mar 31, 2023 | 0.21% |
| Dec 31, 2022 | 0.27% |
| Sep 30, 2022 | 0.40% |
| Jun 30, 2022 | 0.00% |
| Mar 31, 2022 | 0.00% |
| Dec 31, 2020 | 0.32% |
| Sep 30, 2020 | 0.37% |
| Jun 30, 2020 | 0.43% |